ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is KYORIN Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 4.46%
- The company has been able to generate a Return on Equity (avg) of 4.46% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with a 17.27% CAGR growth in Operating Profits over the last 5 years
- The company has been able to generate a Return on Equity (avg) of 4.46% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 4.62% and Operating profit at 17.27% over the last 5 years
4
Negative results in Jun 26
- NET PROFIT(HY) At JPY 189.1 MM has Grown at -97.86%
- ROCE(HY) Lowest at 1.57%
- RAW MATERIAL COST(Y) Grown by 6.51% (YoY)
5
With ROE of 7.84%, it has a very attractive valuation with a 0.49 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -29.14%, its profits have risen by 188.1% ; the PEG ratio of the company is 0
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to KYORIN Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is KYORIN Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
KYORIN Pharmaceutical Co., Ltd.
-29.36%
-1.49
23.22%
Japan Nikkei 225
60.14%
2.04
29.37%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.62%
EBIT Growth (5y)
17.27%
EBIT to Interest (avg)
65.84
Debt to EBITDA (avg)
0.51
Net Debt to Equity (avg)
0.08
Sales to Capital Employed (avg)
0.79
Tax Ratio
22.51%
Dividend Payout Ratio
94.97%
Pledged Shares
0
Institutional Holding
0.11%
ROCE (avg)
4.68%
ROE (avg)
4.46%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.49
EV to EBIT
5.62
EV to EBITDA
4.23
EV to Capital Employed
0.52
EV to Sales
0.59
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
9.34%
ROE (Latest)
7.84%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at 4.48 %
-14What is not working for the Company
NET PROFIT(HY)
At JPY 189.1 MM has Grown at -97.86%
ROCE(HY)
Lowest at 1.57%
RAW MATERIAL COST(Y)
Grown by 6.51% (YoY
NET SALES(Q)
At JPY 29,654 MM has Fallen at -6.05%
Here's what is working for KYORIN Pharmaceutical Co., Ltd.
Debt-Equity Ratio
Lowest at 4.48 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for KYORIN Pharmaceutical Co., Ltd.
Net Profit
At JPY 189.1 MM has Grown at -97.86%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Net Sales
At JPY 29,654 MM has Fallen at -6.05%
over average net sales of the previous four periods of JPY 31,564.25 MMMOJO Watch
Near term sales trend is negative
Net Sales (JPY MM)
Raw Material Cost
Grown by 6.51% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Non Operating Income
Highest at JPY 0.28 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
